108.FIRST CHOICE OF ANTIPLATELET
A.ASPIRIN
B.CLOPIDOGREL
C.DYPYRIDAMOLE
D.TICLOPIDINE
ANS:ASPIRIN
Antiplatelet drugs
First choice: ASPIRIN
Aspirin (dispersible tablets) should be used after myocardial infarction, in unstable and stable angina, for primary prevention in high-risk individuals, in patients with a strong family history of bowel cancer, in "low-risk" patients in atrial fibrillation and in thrombotic cerebrovascular disease. There is no conclusive evidence that enteric-coated preparations in general are better tolerated. In acute myocardial infarction, a loading dose of 300mg of dispersible or crushed (if enteric-coated) aspirin is given as early as possible after the onset of symptoms, followed by a daily maintenance dose of 150mg daily for at least one month. Thereafter, a daily maintenance dose of 75 - 150mg dispersible is suggested.
SPECIAL INDICATIONS
Abciximab (IV injection) is a monoclonal antibody, which inhibits platelet aggregation and thrombus formation. It is used by specialists as an adjunct to heparin and aspirin for the prevention of ischaemic complications in high-risk patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
Dipyridamole (m/r capsules) in the modified-release formulation is used for secondary prevention of ischaemic stroke. An injectable form is used for certain diagnostic purposes such as myocardial perfusion imaging.
Clopidogrel (75mg tablets) is a prodrug. One of its metabolites inhibits platelet aggregation by irreversibly and selectively blocking adenosine diphosphate (ADP) at its platelet receptor. It is used in the treatment of ischaemic heart disease. Its use is restricted to patients who are truly intolerant to aspirin. It is contra-indicated in patients at high risk of GI bleeds. It can also be used in combination with aspirin in stented angioplasty, administered for 2 days before and for 4 weeks after the procedure. It is used in combination with aspirin for up to one year for unstable angina or acute coronary syndrome and four weeks in patients with ST segment elevation acute myocardial infarction.
A.ASPIRIN
B.CLOPIDOGREL
C.DYPYRIDAMOLE
D.TICLOPIDINE
ANS:ASPIRIN
Antiplatelet drugs
First choice: ASPIRIN
Aspirin (dispersible tablets) should be used after myocardial infarction, in unstable and stable angina, for primary prevention in high-risk individuals, in patients with a strong family history of bowel cancer, in "low-risk" patients in atrial fibrillation and in thrombotic cerebrovascular disease. There is no conclusive evidence that enteric-coated preparations in general are better tolerated. In acute myocardial infarction, a loading dose of 300mg of dispersible or crushed (if enteric-coated) aspirin is given as early as possible after the onset of symptoms, followed by a daily maintenance dose of 150mg daily for at least one month. Thereafter, a daily maintenance dose of 75 - 150mg dispersible is suggested.
SPECIAL INDICATIONS
Abciximab (IV injection) is a monoclonal antibody, which inhibits platelet aggregation and thrombus formation. It is used by specialists as an adjunct to heparin and aspirin for the prevention of ischaemic complications in high-risk patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
Dipyridamole (m/r capsules) in the modified-release formulation is used for secondary prevention of ischaemic stroke. An injectable form is used for certain diagnostic purposes such as myocardial perfusion imaging.
Clopidogrel (75mg tablets) is a prodrug. One of its metabolites inhibits platelet aggregation by irreversibly and selectively blocking adenosine diphosphate (ADP) at its platelet receptor. It is used in the treatment of ischaemic heart disease. Its use is restricted to patients who are truly intolerant to aspirin. It is contra-indicated in patients at high risk of GI bleeds. It can also be used in combination with aspirin in stented angioplasty, administered for 2 days before and for 4 weeks after the procedure. It is used in combination with aspirin for up to one year for unstable angina or acute coronary syndrome and four weeks in patients with ST segment elevation acute myocardial infarction.
No comments:
Post a Comment